BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Queensland Health

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,349,085

« Back to Dashboard

Summary for Patent: 5,349,085

Title: X-ray contrast agents
Abstract:Compounds of the general formula: ##STR1## (where R is a group --CH(CH.sub.2 OH).sub.2 or --CH.sub.2 CH(OH)CH.sub.2 OH and A is a group --CH.sub.2 CH(OH)CH.sub.2 -- or --CH.sub.2 CH(OH)CH(OH)CH.sub.2 --) possess a package of favourable parameters which render them of particular use not only in all forms of intravascular visualisation but also in myelography. The compounds are prepared by reaction of an appropriate 5-acetylamino-N,N'-bis(hydroxypropyl)-2,4,6-triiodoisophthalamide with an agent effective to introduce the appropriate hydroxyalkylene group such as for example epichlorohydrin or 1,4-dichloro-2,3-dihydroxybutane.
Inventor(s): Hansen; Per-Egil (Dalbo, NO), Holtermann; Hugo (Hovik, Baerum, NO), Wille; Knut (Oster.ang.s, NO)
Assignee: Nycomed Imaging AS (Oslo, NO)
Application Number:07/960,231
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: 5,349,085

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8231796Nov 08, 1982

International Patent Family for Patent: 5,349,085

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0108638► SubscribeSPC/GB93/150United Kingdom► Subscribe
European Patent Office0108638► Subscribe97C0101Belgium► Subscribe
Denmark508283► Subscribe
Denmark160868► Subscribe
Hong Kong46791► Subscribe
Austria20733► Subscribe
Germany3364536► Subscribe
JapanS59104352► Subscribe
JapanS6355509► Subscribe
Luxembourg88639► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus